omeprazole has been researched along with Kidney Diseases in 11 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the case of a 51-year-old man in whom uncontrollable vomiting, treatment with omeprazole and thiazide, and renal impairment lead to a severe hypomagnesemia (magnesium below the level of detection in blood tests), which secondarily caused Wernicke's encephalopathy and vasospasm in multiple cerebral arteries (seen with cerebral angiography and CT angiography) that presented with a complete right hemisphere neurological deficit." | 3.83 | Cerebral vasospasm and wernicke encephalopathy secondary to adult cyclic vomiting syndrome: the role of magnesium. ( García-Muñozguren, S; Hernández-Fernández, F; Peinado-Ródenas, J; Sánchez-Larsen, Á; Segura, T; Zamarro, J, 2016) |
| " Following a single oral dose of 40 mg, Cmax is approximately 2." | 2.68 | Pharmacokinetics of pantoprazole in man. ( Bliesath, H; Hartmann, M; Huber, R; Lühmann, R; Steinijans, VW; Zech, K, 1996) |
| " If two drugs of the same class have a similar dose-efficacy profile, then the favourable/unfavourable balance of the pharmacokinetic characteristics of the drugs may determine the drug of choice." | 2.39 | Pharmacokinetics--a relevant factor for the choice of a drug? ( Benet, LZ; Zech, K, 1994) |
| " A significant, although weak, relationship existed between creatinine clearance (CLCR) and area under the plasma concentration versus time curve (AUC) and terminal disposition half-life (t1/2), calculated with total concentration data." | 1.30 | Lansoprazole pharmacokinetics in subjects with various degrees of kidney function. ( Cavanaugh, JM; Karol, MD; Machinist, JM, 1997) |
| "She had been suffering from gastroduodenal ulcer for about ten years." | 1.29 | [A case report of prosthetic valve replacement for malfunction of the Hancock valve in mitral position associated with recurrent peptic ulcer and renal dysfunction]. ( Aomi, S; Fujino, S; Hashimoto, A; Hirai, M; Koyanagi, H; Koyanagi, T; Sakahashi, H; Tokunaga, H, 1995) |
| "Omeprazole was rapidly cleared and possessed the characteristics of a high clearance drug; insignificant amounts of 14C-omeprazole were excreted by the kidneys, though metabolites were excreted very rapidly." | 1.27 | Pharmacokinetics and metabolism of omeprazole in man. ( Regårdh, CG, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Varallo, FR | 1 |
| de Nadai, TR | 1 |
| de Oliveira, ARA | 1 |
| Mastroianni, PC | 1 |
| Abou Ziki, MD | 1 |
| Verjee, MA | 1 |
| Sánchez-Larsen, Á | 1 |
| Segura, T | 1 |
| García-Muñozguren, S | 1 |
| Peinado-Ródenas, J | 1 |
| Zamarro, J | 1 |
| Hernández-Fernández, F | 1 |
| Wang, L | 1 |
| Zhang, H | 1 |
| Li, C | 1 |
| Yi, Y | 1 |
| Liu, J | 1 |
| Zhao, Y | 1 |
| Tian, J | 1 |
| Zhang, Y | 1 |
| Wei, X | 1 |
| Gao, Y | 1 |
| Liang, A | 1 |
| Tsukada, K | 1 |
| Miyazaki, T | 1 |
| Katoh, H | 1 |
| Masuda, N | 1 |
| Ojima, H | 1 |
| Fukai, Y | 1 |
| Nakajima, M | 1 |
| Manda, R | 1 |
| Fukuchi, M | 1 |
| Kuwano, H | 1 |
| Tsukada, O | 1 |
| Nurmohamed, MT | 1 |
| Lems, WF | 1 |
| Hirai, M | 1 |
| Hashimoto, A | 1 |
| Aomi, S | 1 |
| Tokunaga, H | 1 |
| Koyanagi, T | 1 |
| Sakahashi, H | 1 |
| Fujino, S | 1 |
| Koyanagi, H | 1 |
| Benet, LZ | 1 |
| Zech, K | 2 |
| Huber, R | 1 |
| Hartmann, M | 1 |
| Bliesath, H | 1 |
| Lühmann, R | 1 |
| Steinijans, VW | 1 |
| Karol, MD | 1 |
| Machinist, JM | 1 |
| Cavanaugh, JM | 1 |
| Regårdh, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense[NCT02278432] | 427 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for omeprazole and Kidney Diseases
| Article | Year |
|---|---|
Pharmacokinetics--a relevant factor for the choice of a drug?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aging; Benzimidazoles; Biological Ava | 1994 |
2 trials available for omeprazole and Kidney Diseases
| Article | Year |
|---|---|
Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients.
Topics: Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2002 |
Pharmacokinetics of pantoprazole in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer A | 1996 |
8 other studies available for omeprazole and Kidney Diseases
| Article | Year |
|---|---|
Potential Adverse Drug Events and Nephrotoxicity Related to Prophylaxis With Omeprazole for Digestive Disorders: A Prospective Cohort Study.
Topics: Aged; Creatinine; Digestive System Diseases; Double-Blind Method; Female; Humans; Kidney Diseases; M | 2018 |
Rare mutation in the SLC26A3 transporter causes life-long diarrhoea with metabolic alkalosis.
Topics: Adult; Alkalosis; Bicarbonates; Chloride-Bicarbonate Antiporters; Chlorides; Diarrhea; Female; Human | 2015 |
Cerebral vasospasm and wernicke encephalopathy secondary to adult cyclic vomiting syndrome: the role of magnesium.
Topics: Diagnosis, Differential; Humans; Kidney Diseases; Magnesium; Male; Middle Aged; Omeprazole; Proton P | 2016 |
Omeprazole Alleviates Aristolochia manshuriensis Kom-Induced Acute Nephrotoxicity.
Topics: Acute Disease; Animals; Aristolochia; Aristolochic Acids; Cytochrome P-450 CYP1A1; Epithelial Cells; | 2016 |
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Contraindications; Cyclooxyge | 2003 |
[A case report of prosthetic valve replacement for malfunction of the Hancock valve in mitral position associated with recurrent peptic ulcer and renal dysfunction].
Topics: Female; Heart Valve Prosthesis; Humans; Kidney Diseases; Middle Aged; Mitral Valve; Omeprazole; Pept | 1995 |
Lansoprazole pharmacokinetics in subjects with various degrees of kidney function.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Area Under Curve; Case-Control Studies; Half-L | 1997 |
Pharmacokinetics and metabolism of omeprazole in man.
Topics: Administration, Oral; Aged; Aging; Anti-Ulcer Agents; Benzimidazoles; Diazepam; Dose-Response Relati | 1986 |